ADHD drug combo trial halted early
NCT ID NCT06673368
Summary
This study aimed to see if adding a new medicine (NRCT-101SR) to a standard ADHD drug (NRCT-202XR) works better and is safe for teens. It planned to enroll about 60 teenagers (ages 13-17) with ADHD for a 6-week period. The trial was terminated early, with only 2 participants enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accel Research Site-Maitland Clinical Research Unit
Maitland, Florida, 32751, United States
-
Boston Clinical Trials LLC
Boston, Massachusetts, 02131, United States
-
CenExel iRS - iResearch Savannah
Savannah, Georgia, 31405, United States
-
Center For Psychiatry and Behavioral Medicine
Las Vegas, Nevada, 89128, United States
-
iResearch Atlanta
Decatur, Georgia, 30030, United States
Conditions
Explore the condition pages connected to this study.